• Curing Data Collection Woes Could Take a Village

    Clinical Research News | The average clinical trial generates three times as much data as it did a decade ago, and yet there are no standards in place for how that information should be collected. That’s a big problem for many reasons, not the least of which is that drug developers may be missing key insights about the way interventions are working in individuals and across populations.

    Oct 8, 2024

  • Study Aims to Resolve Variants of Uncertain Significance

    Clinical Research News | A pioneering study led by Dr. Lachlan Jolly at the University of Adelaide’s Neurobiology Research Group is transforming genetic diagnostics by resolving variants of uncertain significance (VUS) using skin samples. Many patients with VUS lack a definitive diagnosis because RNA from disease-causing genes often can't be extracted from accessible tissues like blood or skin.

    Oct 3, 2024

  • Scope of Things: Trial Planning Skews Conclusions, AI Diversity Help, News of the Month

    Clinical Research News | In this month’s episode of the Scope of Things, host Deborah Borfitz covers everything you need to know about a pending launch of a large treatment trial for Graves’ disease, a recruitment campaign for a diagnostic tampon, Walgreens and BARDA’s new partnership, how eligibility criteria has been excluding people of African or Middle Eastern descent from cancer studies, and more.

    Oct 2, 2024

  • Follow the Money: GPCR Targets, Upacicalcet, AAV-Delivered Cancer Immunotherapy, More

    Clinical Research News | Superluminal Medicines is focusing on supporting the progression of their lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets; Pathalys Pharma wraps up upacicalcet clinical trials; Vironexis anticipates initiating patient enrollment of a Phase 1/2 trial of VNX-101 in the fourth quarter of 2024, which will mark the first-ever clinical trial of an AAV-delivered cancer immunotherapy; and more.

    Sep 26, 2024

  • AstraZeneca, Moffitt Cancer Center Partner, Firefly Neuroscience Advances AI Tech, More

    Clinical Research News | Moffitt Cancer Center announced a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell and T cell receptor therapies; Firefly Neuroscience announced the advancement of its artificial intelligence-powered Brain Network Analytics (BNA) technology; and more.

    Sep 25, 2024

  • PCORI Offers $100 Million For Youth Research, Children’s Health Promotion

    Clinical Research News | PCORI announced earlier this month that they are inviting proposals through eight new funding opportunities. These include three PCORI Funding Announcements for patient-centered comparative clinical effectiveness research (CER). Letters of intent are due October 1, 2024, and applications will be accepted until January 14, 2025.

    Sep 24, 2024

  • Flatiron Health Expands its Mission to Make Trials More ‘Pragmatic’

    Clinical Research News | The patient groups more likely to be treated at community practices with limited or no access to oncology clinical trials are the same groups historically underrepresented in such trials, finds a nationwide study conducted by Flatiron Health. The reasons for this are unknown, but the research effectively rules out quality of care and location of the practices.

    Sep 19, 2024

  • Trial Emulation Study Taps Real-World Data to Help Fill Evidence Gaps

    Clinical Research News | Researchers in the UK recently emulated a large, randomized controlled trial (RCT) testing the effectiveness of two blood thinners using data from real-world patients to help understand whether the real-world data can be used to explore treatment effects in people underrepresented in the study. While results of the reference trial and its simulation didn’t entirely align, the approach could help fill the evidence gap for population groups largely missing in RCTs.

    Sep 17, 2024

  • New Treatment Option for Graves’ Disease Finally ‘On the Horizon’

    Clinical Research News | Later this year, Immunovant will be launching a late-stage clinical trial for Graves’ disease—the first in a very, very long time. The preferred treatment option currently is methimazole, approved for medical use in the U.S. in 1950, but some patients require high doses of the drug to control their hyperthyroidism, and in up to half of cases long-term remission isn’t achievable short of surgery to remove the thyroid gland or radioactive iodine to destroy the thyroid and stop it from producing hormones.

    Sep 12, 2024